Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer

Abstract

Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.

References36

[1]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chin Med J (Engl),2021,134(7): 783-791. DOI:10.1097/CM9.0000000000001474.
[2]	Chen M, Li C, Sun M, et al. Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies[J].Front Immunol,2022,13: 1043517. DOI:10.3389/fimmu.2022.1043517.
[3]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J].Lancet,2021,398(10294): 27-40. DOI:10.1016/S0140-6736(21)00797-2. pmid:34102137
[4]	Xu JM, Jiang H, Pan Y, et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase Ⅲ study[J].Ann Oncol,2021,32: S1331. DOI:10.1016/j.annonc.2021.08.2133.
[5]	Gao Y, Li S, Xu D, et al. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T_1-4N₊M₀gastric adenocarcinoma[J].Chin J Cancer,2017,36(1): 61. DOI:10.1186/s40880-017-0226-3.
[6]	Park Y, Koh J, Na HY, et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs[J].Cancer Res Treat,2020,52(3): 661-670. DOI:10.4143/crt.2019.718. pmid:32019283
[7]	Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer[J].Gastric Cancer,2015,18(3): 476-484. DOI:10.1007/s10120-014-0402-y. pmid:25038874
[8]	Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J].Lancet,2023,402(10418): 2197-2208. DOI:10.1016/S0140-6736(23)02033-0. pmid:37871604
[9]	Lian J, Zhang G, Zhang Y, et al. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance[J].Dig Liver Dis,2022,54(10): 1419-1427. DOI:10.1016/j.dld.2022.01.128.
[10]	Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial[J].Lancet Oncol,2020, 21(8): 1066-1076. DOI:10.1016/S1470-2045(20)30326-0.
[11]	Triulzi T, Forte L, Regondi V, et al. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy[J].Oncoimmunology,2018,8(1): e1512942. DOI:10.1080/2162402X.2018.1512942.
[12]	Yagi S, Wakatsuki T, Yamamoto N, et al. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer[J].Gastric Cancer,2019,22(3): 518-525. DOI:10.1007/s10120-018-0887-x. pmid:30328533
[13]	Park SR, Park YS, Ryu MH, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1)[J].Eur J Cancer,2016,53: 42-50. DOI:10.1016/j.ejca.2015.09.018. pmid:26693898
[14]	Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)[J].Gastric Cancer,2019,22(3): 527-535. DOI:10.1007/s10120-018-0891-1. pmid:30386954
[15]	Choi S, Park S, Kim H, et al. Gastric cancer: mechanisms, biomarkers, and therapeutic approaches[J].Biomedicines,2022,10(3): 543. DOI:10.3390/biomedicines10030543.
[16]	Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J].Cancer Res,2019,79(18): 4557-4566. DOI:10.1158/0008-5472.CAN-18-3962. pmid:31350295
[17]	Tian C, Jing H, Wang C, et al. Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis[J].BMJ Open,2021,11(1): e044163. DOI:10.1136/bmjopen-2020-044163.
[18]	吴杨, 陈雨琪, 石通国, 等. 胃癌患者免疫微环境中表型特征及其与临床病理参数和预后的关系[J].中华医学杂志,2023,103(35): 2786-2794. DOI:10.3760/cma.j.cn112137-20230314-00394.
[19]	Mori T, Tanaka H, Suzuki S, et al. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer[J].Cancer Sci,2021,112(5): 1746-1757. DOI:10.1111/cas.14888.
[20]	He W, Zhang D, Liu H, et al. The high level of tertiary lymphoid structure is correlated with superior survival in patients with advanced gastric cancer[J].Front Oncol,2020,10: 980. DOI:10.3389/fonc.2020.00980. pmid:32733793
[21]	Yin YX, Ling YH, Wei XL, et al. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients[J].Front Immunol,2022,13: 973085. DOI:10.3389/fimmu.2022.973085.
[22]	Jiang Q, Tian C, Wu H, et al. Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer[J].Chin J Cancer Res,2022,34(4): 365-382. DOI:10.21147/j.issn.1000-9604.2022.04.05.
[23]	Lugli A, Zlobec I, Berger MD, et al. Tumour budding in solid cancers[J].Nat Rev Clin Oncol,2021,18(2): 101-115. DOI:10.1038/s41571-020-0422-y.
[24]	Xue C, Du Y, Li Y, et al. Tumor budding as a predictor for prognosis and therapeutic response in gastric cancer: a mini review[J].Front Oncol,2022,12: 1003959. DOI:10.3389/fonc.2022.1003959.
[25]	Zhang N, Wang D, Duan Y, et al. The special immune microenvironment of tumor budding and its impact on prognosis in gastric adenocarcinoma[J].Pathol Res Pract,2020,216(6): 152926. DOI:10.1016/j.prp.2020.152926.
[26]	Ulase D, Heckl S, Behrens HM, et al. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the international tumour budding consensus conference[J].Histopathology,2020,76(3): 433-446. DOI:10.1111/his.13997. pmid:31538348
[27]	Szalai L, Jakab Á, Kocsmár I, et al. Prognostic ability of tumor budding outperforms poorly differentiated clusters in gastric cancer[J].Cancers (Basel),2022,14(19): 4731. DOI:10.3390/cancers14194731.
[28]	Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship[J].Biochim Biophys Acta Rev Cancer,2020,1873(2):188356. DOI:10.1016/j.bbcan.2020.188356.
[29]	Aurello P, Berardi G, Giulitti D, et al. Tumor-stroma ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients[J].Surgeon,2017,15(6): 329-335. DOI:10.1016/j.surge.2017.05.007.
[30]	Kim EY, Abdul-Ghafar J, Chong Y, et al. Calculated tumor-associated neutrophils are associated with the tumor-stroma ratio and predict a poor prognosis in advanced gastric cancer[J].Biomedicines,2022,10(3): 708. DOI:10.3390/biomedicines10030708.
[31]	Qu Z, Wang Q, Wang H, et al. The effect of inflammatory markers on the survival of advanced gastric cancer patients who underwent anti-programmed death 1 therapy[J].Front Oncol,2022,12: 783197. DOI:10.3389/fonc.2022.783197.
[32]	Chen Y, Zhang C, Peng Z, et al. Association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor[J].Front Oncol,2021,11: 589022. DOI:10.3389/fonc.2021.589022.
[33]	Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial[J].Lancet,2023,401(10389): 1655-1668. DOI:10.1016/S0140-6736(23)00620-7. pmid:37068504
[34]	Rohde C, Yamaguchi R, Mukhina S, et al. Comparison of claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma[J].Jpn J Clin Oncol,2019,49(9): 870-876. DOI:10.1093/jjco/hyz068. pmid:31087075
[35]	Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase Ⅱ study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J].Ann Oncol,2021,32(5): 609-619. DOI:10.1016/j.annonc.2021.02.005. pmid:33610734
[36]	Gao J, Wang Z, Jiang W, et al. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation[J].J Immunother Cancer,2023,11(6): e006704. DOI:10.1136/jitc-2023-006704.

Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References36

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[6]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[7]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[8]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.
[9]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[10]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[11]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[12]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[13]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[14]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[15]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.